Available GLP-1 Treatments in the UK Several GLP-1 receptor agonists are currently licensed and available in the UK, each with distinct characteristics regarding administration, efficacy, and approved indications
Here, she offers tips for the transition
To improve gastrointestinal tolerability, the patients assigned to the 10 or 15 mg doses of tirzepatide were up-titrated to final doses, with those in the 10 mg group receiving a 5 mg dose for the first two weeks and then a 10 mg dose for the remainder of the study, whereas the subjects in the 15 mg group were given a 5 mg dose for the first two weeks, a 10 mg dose for the next four weeks, and a 15 mg dose for the remaining study duration
The medications work the same way, but insurance coverage and labeling differ.
New research underway More trials are now starting to look at how GLP-1s might influence things like chronic inflammation or immunosuppression, both of which might contribute to cancer growth